Abstract #3047

Assessment of Response to Therapy by DCE-MRI & DWI MRI in Primary Liver Cancers

David H. Gultekin¹, Lawrence H. Schwartz², Nancy E. Kemeny³, Mithat Gonen⁴, Michael I. D'Angelica⁵, Peter J. Allen⁵, Yuman Fong⁵, Leslie H. Blumgart⁵, Ronald P. Dematteo⁵, William R. Jarnagin⁵

¹Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; ²Radiology, Columbia University Medical Center, New York, NY, United States; ³Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; ⁴Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, United States; ⁵Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States

The role of DCE-MRI and DWI-MRI have been evaluated in a Phase II study for the assessment of response to therapy in patients with unresectable primary liver cancers, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), undergoing regional combination chemotherapy and anti-angiogenic therapy through continuous hepatic arterial infusion (HAI) treatment procedure.